{"article_title": "House moves to boost research funding, loosen regulation", "article_keywords": ["loosen", "funding", "drugs", "house", "medical", "bill", "legislation", "major", "devices", "research", "regulation", "drug", "moves", "boost"], "article_url": "http://www.latimes.com/nation/nationnow/la-na-congress-drug-funding-20150710-story.html", "article_text": "The House of Representatives overwhelmingly approved legislation Friday to speed approval of drugs and medical devices and boost funding for medical research, pushing forward a major overhaul of the federal government\u2019s regulation of key parts of the healthcare system.\n\nThe legislation, which is backed by major industry groups as well as some leading patient advocates, drew unusually bipartisan support.\n\nThe bill passed 344-77, as 170 Republicans and 174 Democrats voted for it, brushing aside warnings from consumer watchdog groups that loosening oversight of prescription drugs and medical devices could harm patients.\n\nThe bill awaits action by the Senate, where lawmakers are crafting their own legislation, expected later this year.\n\nThe House bill, titled the 21st Century Cures Act, has been driven by House Energy and Commerce Committee Chairman Fred Upton (R-Mich.), who has billed it as vital to giving patients quicker access to lifesaving treatments.\n\n\u201cThe history of health innovation is indeed remarkable,\u201d Upton said on the House floor. \u201cThis bill is about making sure our laws, regulations and resources keep pace with scientific advances.\u201d\n\nA centerpiece of the bill is $8.75 billion in new funding for the National Institutes of Health at a time when the agency\u2019s research budget has been flat for more than a decade.\n\nThat has helped draw Democratic support, even at a time when the two parties are headed toward a major showdown over broader government spending.\n\nThe new research money also rallied the American Heart Assn., American Cancer Society Cancer Action Network and other medical groups.\n\nProvisions in the legislation that would change the way the Food and Drug Administration reviews drugs and devices are more controversial.\n\nThe bill, for example, would loosen regulatory oversight of changes device makers make to previously approved devices, a process that is already under fire following the deaths of patients in Los Angeles and elsewhere who contracted deadly infections from scopes that were not properly cleaned.\n\nPublic safety activists also worry the legislation could allow new drugs to be approved based on less rigorous trials.\n\n\u201cWe should be clear this is a deregulatory bill that has some funding in it to win votes,\u201d said Vijay Das, a policy advocate at Public Citizen.\n\nEven some supporters have raised questions about the regulatory changes.\n\n\u201cIt is our hope that any final legislation would not inappropriately lower evidentiary standards required for drug and device approval,\u201d Dr. Elliott Antman, immediate past president of the American Heart Assn., warned in letter to lawmakers last month.\n\nAlso drawing criticism is a section of the bill that would loosen disclosure requirements on drug and device makers, which currently must publicly report payments and other gifts they make to physicians under a section of the 2010 Affordable Care Act.\n\nThe White House this week offered qualified support for the bill while registering concerns with several parts of the legislation, including its funding.\n\nThe additional research money would be largely paid for by selling millions of barrels of the federal government\u2019s strategic petroleum reserve.\n\nAnother provision of the legislation that would give pharmaceutical companies an additional six months of patent protection on some drugs used for rare diseases would cost taxpayers $869 million over the next decade, according to the nonpartisan Congressional Budget Office.\n\nStill another part of the bill that would allow hospitals to bill the government for using new, costlier antibiotics would cost more than $500 million.\n\nTwitter: @noamlevey", "article_metadata": {"fb_title": "House moves to boost research funding, loosen regulation", "Description": "The House of Representatives overwhelmingly approved legislation Friday to speed approval of drugs and medical devices and boost funding for medical research, pushing forward a major overhaul of the federal government\u2019s regulation of key parts of the healthcare system.   The legislation, which is...", "copyright": "Copyright (c) 2016 Los Angeles Times", "author": "Los Angeles Times", "og": {"site_name": "latimes.com", "description": "The House of Representatives overwhelmingly approved legislation Friday to speed approval of drugs and medical devices and boost funding for medical research, pushing forward a major overhaul of the federal government\u2019s regulation of key parts of the healthcare system.", "title": "House moves to boost research funding, loosen regulation", "url": "http://www.latimes.com/nation/nationnow/la-na-congress-drug-funding-20150710-story.html", "image": "http://www.trbimg.com/img-559fe177/turbine/la-na-congress-drug-funding-20150710", "type": "article"}, "x-servername": "lalvp11.13", "twitter": {"site": "@latimes", "card": "summary"}, "msvalidate.01": "AAC9C18F70AC386BC4DCF4DDF9BF1786", "robots": "index,follow", "apple-itunes-app": "app-id=373238146, app-argument=http://www.latimes.com/deeplinkid/83967454", "fb": {"admins": 100000786395051, "page_id": 5863113009}, "googlebot-news": "index", "date": "2015-07-10", "y_key": "cee2fe4077f8d050", "viewport": "width=device-width, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0, user-scalable=no", "googlebot": "index"}, "_id": "\"57477af36914bd0286fc9a10\"", "article_summary": "The House of Representatives overwhelmingly approved legislation Friday to speed approval of drugs and medical devices and boost funding for medical research, pushing forward a major overhaul of the federal government\u2019s regulation of key parts of the healthcare system.\nThe House bill, titled the 21st Century Cures Act, has been driven by House Energy and Commerce Committee Chairman Fred Upton (R-Mich.), who has billed it as vital to giving patients quicker access to lifesaving treatments.\nThe White House this week offered qualified support for the bill while registering concerns with several parts of the legislation, including its funding.\nThe new research money also rallied the American Heart Assn., American Cancer Society Cancer Action Network and other medical groups.\nProvisions in the legislation that would change the way the Food and Drug Administration reviews drugs and devices are more controversial."}